Vertex Pharmaceuticals to Advance VX-548 Pain Drug After Positive Phase 2 Studies

By Colin Kellaher

Vertex Pharmaceuticals Inc. on Thursday said it plans to advance VX-548 into pivotal development after the investigational pain drug showed positive results in a pair of Phase 2 proof-of-concept studies.

The Boston drug maker said VX-548 met the primary endpoint in both studies of acute pain following abdominoplasty or bunionectomy surgery.

Vertex said VX-548 was generally well tolerated, and it plans to advance the drug into pivotal development in acute pain in the second half of the year following discussions with regulators.

Write to Colin Kellaher at [e-mail]

(END) Dow Jones Newswires

03-31-22 0845ET